Bristol-Myers Squibb Company with ticker code (BMY) have now 22 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The range between the high target price and low target price is between $90.00 and $50.00 calculating the mean target price we have $63.23. Given that the stocks previous close was at $50.23 this would imply there is now a potential upside of 25.9%. It’s also worth noting that there is a 50 day moving average of $53.23 and the 200 day MA is $62.07. The market capitalization for the company is 101.49B. The current share price for the company is: $49.88 USD
The potential market cap would be $127,761,389,382 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 12.66, revenue per share of $21.51 and a 5.59% return on assets.
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
